Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Knight Therapeutics Inc KHTRF


Primary Symbol: T.GUD

Healthcare
Knight Therapeutics Inc. is a Canada-based specialty pharmaceutical company. The Company's principal business activity includes developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada... see more

Recent & Breaking News (TSX:GUD)

Knight Announces Filing of Preliminary Base Shelf Prospectus

GlobeNewswire December 10, 2020

Knight Therapeutics Reports Third Quarter 2020 Results

GlobeNewswire November 13, 2020

Notice of Knight Therapeutics' Third Quarter 2020 Results Conference Call

GlobeNewswire November 6, 2020

Knight Signs New Exclusive AmBisome® Agreement with Gilead in Brazil

GlobeNewswire October 26, 2020

Knight Therapeutics Announces Filling of Supplement to a New Drug Submission for NERLYNX® (neratinib) to Treat HER2-Positive Metastatic Breast Cancer

GlobeNewswire September 3, 2020

Knight and TherapeuticsMD Announce Health Canada Approval of IMVEXXY®

GlobeNewswire August 25, 2020

Knight Therapeutics Completes the Tender Offer for Grupo Biotoscana And Achieves Over 95% Ownership

GlobeNewswire August 14, 2020

Knight Therapeutics Reports Second Quarter 2020 Results

GlobeNewswire August 13, 2020

Notice of Knight Therapeutics' Second Quarter 2020 Results Conference Call

GlobeNewswire August 6, 2020

Knight Therapeutics Announces the Launch of the Tender Offer for remaining 48.8% of Grupo Biotoscana

GlobeNewswire July 15, 2020

Knight Announces Normal Course Issuer Bid

GlobeNewswire July 10, 2020

Knight Therapeutics Announces CVM Approval of the Tender Offer for remaining 48.8% of Grupo Biotoscana

GlobeNewswire July 8, 2020

Knight Therapeutics Reports First Quarter 2020 Results

GlobeNewswire June 26, 2020

Knight Therapeutics Inc. announces voting results from the Annual Meeting

GlobeNewswire June 25, 2020

Notice of Knight Therapeutics' First Quarter 2020 Results Conference Call

GlobeNewswire June 18, 2020

Knight Therapeutics Inc. Announces Further Update on Extension of First Quarter 2020 Filings due to COVID-19

GlobeNewswire May 29, 2020

Knight to Present at the Jefferies 2020 Virtual Global Healthcare Conference

GlobeNewswire May 27, 2020

Knight Therapeutics Inc. Announces Extension of First Quarter 2020 Filings due to COVID-19

GlobeNewswire April 30, 2020

Knight Announces the Re-Launch of Trelstar® in Canada

GlobeNewswire April 20, 2020

Knight Therapeutics Announces Approval of IBSRELA(TM) in Canada

GlobeNewswire April 17, 2020